Klaus Pantel

TL;DR: The results indicate that disseminated breast cancer cells in BM can survive first-line adjuvant chemotherapy and express epithelial cell adhesion molecule (Ep-CAM), recently suggested as promising target for immunotherapeutic interventions in breast cancer.

TL;DR: Although the clinical use of ctDNA as a surrogate biomarker is still hampered by biological and technological hurdles, the implications of a liquid biopsy could be enormous as there would be numerous potential applications including (but not limited to): early detection, monitoring of minimal residual disease (MRD), assessment of treatment response, and triaging based on risk of recurrence.

TL;DR: This is the first study to report that C TCs detected by an automated immunomagnetic detection system are independent, prognostic indicators of patients' outcome in EC, and implementation of CTCs may improve accuracy of preoperative staging in EC.

TL;DR: This review focuses on the process of developing CTC biomarker assays, with the objective of outlining the necessary steps to qualify specific CTC tests for medical decision making in clinical practice or drug development.

TL;DR: As repeat sampling of peripheral blood is more acceptable to patients, the measurement of CTCs warrants further investigation because it enables blood samples to be taken more frequently, thus possibly enabling clinicians to have prior warning of impending overt metastatic disease.